SHARE is an easy-to-search, real-time repository of HIV-related systematic reviews. Whether you’re a researcher, community member, healthcare provider or policymaker, SHARE provides a ‘one-stop shop’ for HIV-related information that has been published through a systematic review.

BACKGROUND: Demand for a future HIV vaccine, similar to other vaccines, is vulnerable to misinformation. A number of studies have examined HIV vaccine acceptability and demand, but few have systematically...

Co-infection of HIV and HBV is still a major global public health concern. Co-infected people have a nearly threefold increased risk of end-stage liver disease, with a noticeably faster development...

Introduction: Fundamental progress has been made in HIV care, and one of the major advances was the implementation of Differentiated Service Delivery (DSD) models. DSD models are important in reducing cost...

Key take-home messages

Human Immunodeficiency Virus (HIV) is a global health problem that causes many deaths, especially in low- and middle-income countries (LMICs). Most HIV cases occur in sub-Saharan Africa and Asia. In...

Key take-home messages

PURPOSE OF REVIEW: Asset mapping aims to engage members of a community to explore and map assets that are solutions to social issues such as homelessness or access to health...

BACKGROUND: The interaction between HIV infection, nutrition and immune system functioning is intricate, leading, in many cases, to a cycle of poor health outcomes. Despite the widespread use of highly...

Purpose: Measuring health-related quality of life across different health states for people with HIV (PWH) using direct or indirect preference-based values can inform decision-analytic models evaluating cost-effectiveness of different care strategies....

Key take-home messages

Objective This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine...

(1) Background: Second-generation integrase strand transfer inhibitors (INSTIs) are now the preferred first-line therapies for human immunodeficiency virus (HIV). However, concerns regarding their side effects, such as weight gain and...